75% of Optometrists Prescribe Blue-Light Lenses Despite Acknowledging Limited Evidence. A Cochrane Review of 17 Trials Found They Make No Difference.

The Upcharge at the Counter

Walk into any optician's office for a new prescription and you will almost certainly be offered a blue-light coating on your lenses. The pitch is simple. Modern screens flood your eyes with harmful blue light that causes digital eye strain, disrupts your sleep, and may damage your retina over time, but for an extra twenty to a hundred dollars, blue-light filtering lenses promise to neutralize the threat. The story is so compelling that it has spawned a $2.9 billion global market as of 2024, growing at 7.3 percent annually even as the evidence base beneath it remains stubbornly empty.

None of them work. A 2018 Australian survey found that 75 percent of 372 optometrists reported prescribing blue-light lenses to patients while simultaneously acknowledging limitations in the evidence supporting their use. The American Academy of Ophthalmology has never recommended them, and neither has the Royal Australian and New Zealand College of Ophthalmologists or the UK's College of Optometrists. Yet the products keep selling, propped up by marketing that confuses the intensity of the sun with the glow of a laptop.

What 17 Trials Showed

In August 2023, eight researchers across three universities published the most comprehensive analysis of blue-light filtering lenses ever conducted. Their Cochrane systematic review scoured every randomized controlled trial comparing blue-light glasses to standard lenses, identifying 17 from six countries that enrolled a combined 619 participants with follow-up ranging from less than a day to five weeks.

The result was unambiguous. Not one trial found a clear benefit. For visual fatigue, the primary endpoint, the mean difference between blue-light and standard lenses was 9.76 units in the wrong direction: blue-light wearers actually reported marginally worse symptoms, with a confidence interval of −33.95 to 53.47 that easily crosses zero. Visual acuity showed zero difference, and sleep results were mixed, with three of six studies reporting improvement and three finding none, the inconsistency explained by population differences rather than the lenses. And retinal protection, one of the industry's loudest claims, was never tested in any of the included trials at all.

The Arithmetic Nobody Ran

Here is a number that belongs on every product label. Computer screens deliver roughly one-thousandth of the blue light that reaches your eyes from natural daylight. Blue-light filtering lenses block between 10 and 25 percent of blue wavelengths, and when you run those numbers together, the result is unflattering for the industry. It barely registers.

If you spend one hour outdoors and eight hours on a screen, the screen contributes approximately 0.8 percent of your total daily blue light exposure, and the best lenses on the market, those filtering 25 percent of blue wavelengths, would remove about 0.2 percent of your daily blue light intake. Thirty minutes outdoors barely shifts the math. Achieving meaningful filtering would require lenses with an obvious amber tint that substantially distorts color perception, making them impractical for the everyday screen use they claim to address.

Step outside for ten minutes and your eyes absorb more blue light than your screen delivers in an entire workday. The premium buys peace of mind, not protection.

The Strongest Case for These Lenses

The most robust defense centers on what the Cochrane review could not assess. The longest study ran five weeks, and most measured outcomes over days, so long-term cumulative effects remain genuinely unknown. Melanopsin-containing retinal ganglion cells are more sensitive to short-wavelength light, and laboratory studies have demonstrated that bright blue-light exposure before bed can suppress melatonin production by up to 50 percent; proponents argue that screen-related blue light could affect sleep and retinal health in ways that only manifest over months or years, in populations underrepresented in the current trials.

This argument deserves its full weight. But those laboratory melatonin studies typically used light sources orders of magnitude brighter than any consumer screen, and the AAO maintains that simply reducing screen time before bed and using built-in night-mode settings, which shift the entire display's spectrum rather than filtering a sliver of it, are more effective and cost nothing. Screens are not the sun. The three positive sleep studies in the review involved populations with psychiatric disorders or extreme light sensitivity, not the general office workers buying these lenses.

What We Didn't Prove

This review cannot rule out long-term effects, since none of the 17 trials exceeded five weeks and the total sample of 619 participants limits statistical power for detecting small effects. The certainty of evidence ranged from "very low" to "moderate" by GRADE criteria, with 65 percent of included studies carrying high risk of detection bias because outcome assessors were not masked and 59 percent at high risk of performance bias because participants knew which lenses they wore. The mixed sleep findings suggest that specific subpopulations with clinical sleep disorders might benefit, but the current data cannot identify them. Retinal protection remains entirely unevaluated in any randomized trial, and individual study sample sizes ranged from five to 156 participants, none adequately powered to detect the small effects the industry claims to deliver.

What You Can Do

Skip the blue-light coating next time you order glasses. The evidence does not justify the premium. If screens bother your eyes, the cause is almost certainly insufficient blinking and sustained close focal distance, not blue light; follow the 20-20-20 rule (every 20 minutes, look at something 20 feet away for 20 seconds). If screen use disrupts your sleep, switch devices to night mode after sunset and avoid screens in the hour before bed. Both interventions are free and better supported by evidence than any lens coating on the market.